Veraxa Biotech, Secarna launch research collaboration on AOCs
Veraxa Biotech entered a strategic research collaboration with Secarna to develop antibody oligonucleotide conjugates for autoimmune and chronic immune diseases, with early in vitro work producing a candidate with higher potency than the equivalent unconjugated oligonucleotide.
VRXA Veraxa Biotech entered a strategic research collaboration with Secarna to develop antibody oligonucleotide conjugates for autoimmune, chronic immune diseases.
Early in vitro work produced an AOC candidate with higher potency than the equivalent unconjugated oligonucleotide.
Partners are discussing next steps, aiming to advance targeted delivery to improve bioavailability, reduce off-target effects.